Prostate cancer (PCa) cell proliferation is dependent on activation of the androgen receptor (AR), a liganddependent transcription factor. AR activation controls G1-S phase progression through fostering enhanced translation of the D-type cyclins, which promote cell cycle progression through activation of CDK4/6. However, the D-type cyclins harbor additional, CDK4/6 kinase-independent, functions through manipulation of transcription factors, including AR. It was previously established that cyclins D1 and D3 have the potential to modulate AR, and with regard to cyclin D1, disruption of this function occurs in human tumors. Therefore, it was essential to interrogate cyclin D3 function in this tumor type. Here, we show that cyclin D3 is found in association with AR in PCa cells, as mediated through a conserved motif. Cyclin D3 functions to attenuate AR activity through defined mechanisms that include modulation of ligand-dependent conformational changes and modulation of chromatin binding activity. Accumulated cyclin D3 slows cell proliferation in AR-dependent cells, thus suggesting that androgen-induced D-type cyclin production serves to temper the mitogenic response to androgen. Supporting this hypothesis, it is shown that cyclin D3 expression is reduced in primary PCas as a function of tumor grade, and inversely correlates with the proliferative index. In total, these data identify cyclin D3 as a critical modulator of the androgen response, whose deregulation may foster unchecked AR activity in PCa.
Prostate cancer (PCa) cell proliferation is dependent on activation of the androgen receptor (AR), a liganddependent transcription factor. AR activation controls G1-S phase progression through fostering enhanced translation of the D-type cyclins, which promote cell cycle progression through activation of CDK4/6. However, the D-type cyclins harbor additional, CDK4/6 kinase-independent, functions through manipulation of transcription factors, including AR. It was previously established that cyclins D1 and D3 have the potential to modulate AR, and with regard to cyclin D1, disruption of this function occurs in human tumors. Therefore, it was essential to interrogate cyclin D3 function in this tumor type. Here, we show that cyclin D3 is found in association with AR in PCa cells, as mediated through a conserved motif. Cyclin D3 functions to attenuate AR activity through defined mechanisms that include modulation of ligand-dependent conformational changes and modulation of chromatin binding activity. Accumulated cyclin D3 slows cell proliferation in AR-dependent cells, thus suggesting that androgen-induced D-type cyclin production serves to temper the mitogenic response to androgen. Supporting this hypothesis, it is shown that cyclin D3 expression is reduced in primary PCas as a function of tumor grade, and inversely correlates with the proliferative index. In total, these data identify cyclin D3 as a critical modulator of the androgen response, whose deregulation may foster unchecked AR activity in PCa.
Introduction D-type cyclins promote cell cycle progression by forming complexes with cyclin-dependent kinase (CDK4/6) partners (Matsushime et al., 1992; Quelle et al., 1993) . Active cyclin D/CDK4/6 phosphorylate the retinoblastoma tumor suppressor, thereby inactivating and releasing the retinoblastoma-mediated transcriptional repression (Ewen et al., 1993; Mittnacht, 1998) . However, additional functions of D-type cyclins exist that are independent of their canonical role in CDK activation (Coqueret, 2002; Knudsen, 2006; Knudsen et al., 2006) . For example, cyclin D1 utilizes CDK4-kinase independent functions to titrate the CDK inhibitors, p21 and p27 from CDK2 complexes, thus promoting G1-S progression (Cheng et al., 1998; Kato et al., 1998; Perry et al., 1998 Perry et al., , 1999 . Additionally, evidence shows that cyclin D1 elicits CDK4-kinase-independent modulation of multiple transcription factors, including DMP1, v-Myb, MyoD and STAT3 (Skapek et al., 1995; Ganter et al., 1998; Inoue and Sherr, 1998; Bienvenu et al., 2001; Coqueret, 2002) . However, the largest cohort of transcription factors modulated by cyclin D1 belong to the nuclear receptor superfamily (Coqueret, 2002; Ewen and Lamb, 2004; Fu et al., 2004) .
Cyclin D1 regulation of nuclear receptors has been extensively explored. In specific cell types, cyclin D1 is found in association with the estrogen receptor a, thyroid hormone receptor, peroxisome proliferatoractivated receptor-g and the androgen receptor (AR) (Neuman et al., 1997; Zwijsen et al., 1998; Knudsen et al., 1999; Reutens et al., 2001; Lin et al., 2002; Petre et al., 2002; Petre-Draviam et al., 2003; Wang et al., 2003; Burd et al., 2005) . With estrogen receptor, cyclin D1 can potentiate receptor activity independently of ligand and CDK4-kinase activity (Neuman et al., 1997) , through formation of a ternary complex with estrogen receptor a and P/CAF, thereby altering chromatin structure to facilitate gene transcription (McMahon et al., 1999) . Cyclin D1 also binds the p160 steroid receptor coactivator, SRC-1, through a conserved nuclear receptor interaction motif (LxxLL) (Zwijsen et al., 1998) , and can enhance estrogen receptor activity in a PKA-dependent manner (Lamb et al., 2000) . The consequence of CDK4-independent cyclin D1 functions has been validated in vivo, wherein knockin of a mutant cyclin D1 deficient in CDK4/6 activation reverses key phenotypes of cyclin D1 À/À mice (for example, hypoplastic mammary glands during pregnancy) (Fantl et al., 1995; Sicinski et al., 1995; Landis et al., 2006) . Thus, CDK4-independent functions of cyclin D1 underpin mammary gland development.
In prostatic cells, cyclin D1 associates with and inhibits AR function, independent of CDK4 activating function and the LxxLL motif (Knudsen et al., 1999; Petre et al., 2002; Burd et al., 2005) . Mechanisms are attributed to a discrete repressor domain, which binds to the AR N-terminus and prevents ligand-dependent conformational changes in AR . Additionally, this motif can recruit histone deacetylase 3 (HDAC3), and the AR-repressor function of cyclin D1 is dependent on HDAC function (Lin et al., 2002; Petre et al., 2002; Petre-Draviam et al., 2005) . Concordantly, the repressor domain of cyclin D1 is also required for cyclin D1-mediated suppression of peroxisome proliferator-activated receptor-g activity (Fu et al., 2005) . These observations led to the hypothesis that while androgen induction of cyclin D1 leads to CDK4 activation and promotes G1-S progression (Knudsen et al., 1998; Xu et al., 2006) , accumulated cyclin D1 regulates this by binding to AR and suppressing subsequent signaling (Knudsen et al., 1999; Reutens et al., 2001; Petre et al., 2002) . Recently, it was observed that this process is disrupted in PCa through alternative splicing of cyclin D1 (which compromises AR regulation), or through aberrant cyclin D1 expression (loss or cytoplasmic sequestration) (Burd et al., 2006; Comstock et al., 2007) . Thus, alterations in cyclin D1 are at least one mechanism to promote AR activity in PCa progression.
Despite the potential importance of cyclin D1 regulation in PCa, few studies have addressed the pleiotropic roles of other D-cyclins. This is critical, as the D-cyclins elicit non-overlapping functions. For example, cyclin D1
À/À mice demonstrate retinopathy and hypoplastic mammary glands (Fantl et al., 1995; Sicinski et al., 1995) , while the cyclin D3 À/À mice have erythroid and lymphoid abnormalities (Sicinska et al., 2003) . Distinctions also exist with regard to granulocyte differentiation, which cyclin D3 inhibits, but for which cyclin D1 has no effect . During muscle differentiation, cyclin D3 is induced while cyclin D1 is repressed (Kiess et al., 1995; Rao and Kohtz, 1995) . Lastly, cyclins D1 and D3 differentially modulate transcription factor activity. Cyclin D1 inhibits peroxisome proliferator-activated receptor-g independently of CDK; however, cyclin D3 enhances peroxisome proliferator-activated receptor-g action through CDK-dependent mechanisms (Wang et al., 2003; Sarruf et al., 2005) . Recent evidence also suggests that maintenance of the liver is mediated, in part, through cyclin D3/CDK4-dependent modulation of C/EBPa/b. Therein, cyclin D3/ CDK4 phosphorylation of CUGBP1 controls C/EBPb translation, thus inhibiting hepatocyte proliferation in aged livers. Lastly, C/EBPa is a target of cyclin D3/ CDK4-mediated phosphorylation that stabilizes growth inhibitory C/EBPa-CDK2 or C/EBPa-Brm complexes (Timchenko et al., 2006; Wang et al., 2006 Wang et al., , 2007 . These observations represent a minority of non-overlapping functions elicited by D-cyclins, regardless of CDKkinase activity.
In the context of PCa models, cyclin D3 translation is induced by androgen and impinges on androgen responsiveness by activating CDK4 (Knudsen et al., 1998; Xu et al., 2006) , but like cyclin D1 has been suggested to retain AR modulatory function (Knudsen et al., 1999) . Herein, the impact of cyclin D3 regulation on AR activity and PCa proliferation was examined, and the biological consequence addressed. This study demonstrates that cyclin D3 associates with AR in PCa cells and represses ligand-dependent activation through CDK4-kinase-independent mechanisms. Mechanistic studies revealed that cyclin D3 acts through a conserved repressor motif to regulate ligand-induced intramolecular interactions, can associate with HDAC3 and impedes AR recruitment to endogenous target genes. Accumulated cyclin D3 slows androgen-dependent proliferation, suggesting that androgen-induced cyclin D3 provides a mechanism to control the pro-proliferative function of AR in PCa. Lastly, tumor analyses demonstrated that cyclin D3 is largely restricted to the cytoplasm in majority of localized cancers, the overall expression is reduced as a function of tumor grade and cyclin D3 expression is inversely correlated with the Ki67 index. Together, the data establish cyclin D3 as a critical regulator of AR activity and suggest that aberrant expression may unleash AR-dependent proliferation in prostatic adenocarcinomas.
Results
Cyclin D3 modulates AR function on multiple target genes It is known that cyclin D3 is expressed in PCa cells, is induced upon androgen stimulation (Knudsen et al., 1998; Xu et al., 2006) and has the capacity to suppress AR activity in transient assays (Knudsen et al., 1999) . Demonstrating this latter function, non-tumorigenic epithelial CV1 cells were transfected in the absence of androgen with expression constructs encoding AR, an AR reporter (PSA6.1-LUC), an AR effector (cyclins D1, D3 or vector) and CMV-b-gal as a control for transfection efficiency. CV1 cells are spontaneously immortalized epithelia that lack endogenous AR and are refractory to hormone status for proliferation (Rundlett et al., 1990 , data not shown). Transfected cells were stimulated with 0.1% ethanol (vehicle control) or 1 nM 5a-dihydro-testosterone (DHT) for 24 h, harvested, lysed and relative reporter activity determined. As expected, both the D-cyclins inhibited the liganddependent transactivation function of AR (but not basal activity) (Figure 1a) . Cyclin D3 reduced AR activity by approximately 65% and cyclin D1 (positive control) demonstrated a similar, and previously observed, capacity to attenuate AR activity (Knudsen et al., 1999; Reutens et Figure S1 ). In the presence of ligand, both cyclin D3 and AR localized to the nucleus (Supplementary Figure S2) , thus indicating that the AR-repressor function of cyclin D3, like cyclin D1, occurs in this subcellular compartment. These data indicate that cyclin D3 can suppress ligand-dependent PSA expression using transient and endogenous assays of AR function.
To address promoter specificity, parallel experiments were performed as in Figure 1a to examine the impact of cyclin D3 on additional target genes. Using the prostatespecific probasin promoter (ARR2-LUC), cyclin D3-repressor function was similar to that observed with PSA (B50% reduction) ( Figure 1c , left panel). By contrast, cyclin D3 demonstrated a more pronounced effect on the sex-limited protein promoter (Slp-HRE3-LUC), reducing androgen-stimulated promoter activity to basal levels ( Figure 1c , right panel). Combined, these data suggest that cyclin D3 can modulate AR activity on various AR target genes, and that the strength of its co-repressor function may be target specific.
Cyclin D3 acts to suppress AR recruitment to PSA locus The observed ability of cyclin D3 to modulate AR function on AR target genes provides a potential mechanism to dissect the molecular events underlying cyclin D3 action. Attempts to knockdown cyclin D3 in AR-dependent PCa cells were inefficient (data not shown), likely owing to the dependence of these cells on CDK4 activity for G1-S progression (Knudsen et al., 1998; Fribourg et al., 2000) . However, cyclin D3 expression is tightly regulated by androgen, where the protein accumulates (via mTOR-mediated induction of cyclin D3 mRNA translation) after 16 h of androgen stimulation (Xu et al., 2006) . Therefore, cell cycle position and androgen status can be used to modulate cyclin D3 status in these cells. Cells were transfected with expression plasmids for cyclin D3 or control, and cultured under conditions of androgen ablation for 72 h, whereupon transfected cells arrest in G1 due to androgen deprivation (data not shown). Consistent with the model, D-cyclins do not advance G1 progression in the absence of androgen (Knudsen et al., 1998; Fribourg et al., 2000) . Cells were then stimulated with 10 nM DHT for 3 h to induce AR activation and recruitment to the PSA locus. As expected, androgen depletion in vector-transfected cells resulted in the loss of cyclin D3 expression, with no observable accumulation within the 3 h androgen exposure time (Figure 2a , compare lanes 1 and 2). By contrast, cyclin D3-transfected cells demonstrated robust expression, regardless of androgen status (lanes 3 and 4). Thus, these protocols provide a stringent mechanism by which we can assess the specific impact of cyclin D3 accumulation on AR activity. As shown by the chromatin immunoprecipitation (ChIP) assay, AR but not cyclin D3 was detected at the PSA locus following 3 h of androgen stimulation (Figure 2b ), which is in contrast to observations with cyclin D1, which is recruited to the PSA locus (LM Morey and KE Knudsen, in preparation). However, cyclin D3 accumulation reduced AR occupancy by 38%. These data indicate that cyclin D3 alters ligand-induced AR residence at a prostate-specific target, and suggest that cyclin D3 elicits effects on AR activity that are distinct from cyclin D1. ) were seeded onto poly-lysine-coated six-well dishes in FBS prior to being transfected in serum-free media with 3 mg of the indicated plasmids. RNA was isolated 48 h after transfection, cDNA was generated and relative PSA expression quantitated by real-time PCR. Expression in vector transfected cells was set to 1. Results shown are a representative experiment of three independent experiments each performed in triplicate, with similar results observed in each experiment. Error bars represent s.e.m.. (c) Experiments were performed as in (a), using ARR2-LUC (left panel) or slp-HRE2-LUC (right panel) as the reporter constructs. AR, androgen receptor; DHT, 5a-dihydro-testosterone; FBS, fetal bovine serum; LNCaP, lymph node prostate cancer.
Cyclin D3 exerts its activity through CDK4-independent mechanisms that parallel cyclin D1 function To assess the requirement of CDK4 for cyclin D3-mediated AR modulation, cells deficient in retinoblastoma expression (Huang et al., 1988) and those that lack substantive CDK4 expression were utilized (Saos-2) (Braden et al., 2006) . Residual cyclin D3/CDK4 is inactive, and due to the lack of retinoblastoma, Saos-2 are refractory to the pro-proliferative activity of CDK/ cyclin D3 (Serrano et al., 1993) . Cells were transfected as indicated using the protocol described for Figure 1a . As demonstrated, cyclin D3 reduced ligand-dependent AR activity by 50% (Figure 3a) , similar to that observed in Figure 1c (left panel), suggesting that cyclin D3 modulation of AR activity is CDK4-independent. Furthermore, ectopic p16
INK4a expression (which inhibits any endogenous CDK4 activity) (Sherr and Roberts, 1995) failed to abrogate cyclin D3-repressor activity (Figure 3a) . Additionally, small-molecule inhibitors of CDK4 failed to alter cyclin D3-mediated AR suppression (data not shown). Together, these data indicate that unlike C/EBP regulation (Timchenko et al., 2006; Wang et al., 2006 Wang et al., , 2007 cyclin D3 acts to block liganddependent AR activation independent of CDK4.
Since cyclin D3 regulates AR activity independently of CDK4, putative mechanisms of action were investigated, based upon knowledge of cyclin D1 function. Previous studies showed that cyclin D1 directly binds to the AR and utilizes two distinct mechanisms to control Figure 1a and transfected with mammalian two-hybrid constructs, VP16-AR-TAD and Gal4-AR-DBD, along with a Gal4-LUC reporter construct, b-gal, cyclin D3 or pcDNA3 (vector control) expression vectors. Following transfections cells were stimulated with 0.1% ethanol or 1 nM DHT for 24 h prior to harvest. Activation of both constructs when transfected with vector and stimulated with DHT was set to 100 and other luciferase activities are shown upon normalization to b-gal. One-way ANOVA was performed to determine statistical significance (*Po0.05). (d) Cos-7 cells were transfected as in (b) using expression plasmids for cyclin D3 and HDAC3. Upon harvest, protein lysates were subjected to immunoprecipitation and subsequent SDS-PAGE separation as described in (b) and immunoblotted to detect cyclin D3. ANOVA, analysis of variance; AR, androgen receptor; CDT, charcoal dextran-treated; DHT, 5a-dihydro-testosterone; HDAC3, histone deacetylase 3; LNCaP, lymph node prostate cancer; SDS-PAGE, SDS-polyacrylamide gel electrophoresis. 6 ) were cultured on poly-lysine-coated 10-cm dishes and were subsequently transfected in serum-free media with 7 mg of the indicated plasmids. Following transfection, cells were cultured in serum-free media for 72 h, and then stimulated with 0.1% vehicle control or 1 nM DHT for 3 h. Cells were then lysed, subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotted to assess cyclin D3 levels. Actin was utilized as a loading control. (b) LNCaP cells were transfected and stimulated with vehicle or DHT as described in (a). Cells were then harvested and subjected to ChIP with the antibodies indicated. ChIP samples were then analysed by quantitative PCR to detect relative recruitment to the PSA enhancer, and plotted from triplicate samples as fold over IgG. One-way ANOVA was performed followed by the Neumann Keuls multiple comparison post-test to determine statistical significance (*Po0.01). The results are representative of three independent experiments, with similar results observed in each experiment. ANOVA, analysis of variance; AR, androgen receptor; ChIP, chromatin immunoprecipitation; DHT, 5a-dihydro-testosterone; LNCaP, lymph node prostate cancer; PSA, prostate-specific antigen.
To determine whether cyclin D3 can bind to AR, co-immunoprecipitation assays were performed after ectopic expression (Supplementary Figure S3) , and between endogenous proteins in PCa cells (Figure 3b , top panel). In both the conditions, AR and cyclin D3 readily associated. Cyclin D3 association with CDK4 was monitored as a positive control (Figure 3b , bottom panel); Dbf4 antisera was the negative control. These data demonstrate that cyclin D3 associates with both CDK4 and AR in PCa cells.
Given the capacity of cyclin D3 to bind AR, functional studies were performed. To determine if cyclin D3 alters the requisitive intramolecular interactions of AR that occur after ligand binding (N-Cterminal interaction) (He et al., 2000; Li et al., 2007) , a well-characterized mammalian two-hybrid assay was utilized (Lim et al., 2000; Burd et al., 2005) where luciferase activity from the Gal4 promoter provided a readout of AR N-C-terminal interaction. Introduction of cyclin D3 resulted in approximately a 75% reduction in N-C-terminal interaction (Figure 3c) . Additionally, the capacity of cyclin D3 to associate with HDAC3 was monitored. As judged by co-immunoprecipitation, cyclin D3 efficiently associates with HDAC3 ( Figure 3d, lane 2) . Combined, these data indicate that cyclin D3 can associate with and repress AR activity through CDK4-independent mechanisms, which likely involve modulation of AR intramolecular interactions and HDAC3 association.
Cyclin D3 contains a conserved repressor domain
The above data indicate that cyclin D3 utilizes mechanisms similar to cyclin D1 in controlling AR function. For cyclin D1, these activities were mapped to a central repressor domain that is sufficient for AR binding and modulation (Petre-Draviam et al., 2005) . Sequence alignment and secondary structure analyses revealed a putative conservation of the repressor domain (RD3) within cyclin D3 (Supplementary Figure S4) . The coding region was therefore cloned, epitope tagged, expression validated by immunoblot following transfection of Cos-7 cells (Figure 4a ) and co-immunoprecipitations were subsequently performed using approaches identical to those in Figure 3d . As shown, AR associated with RD3 ( Figure 4b , middle panel) as compared to cells transfected with vector or cyclin D3-DRD, a construct lacking RD3, indicating that the RD3 is sufficient for AR binding.
To establish the functional consequence of RD3, transcriptional assays were utilized using strategies defined for Figure 1 . Consistent with previous fulllength protein (Figure 1c , left panel), RD3 caused an approximate 75% reduction in ligand-dependent AR activity by reporter assay (Figure 4c) . Similarly, fulllength cyclin D3 and RD3 suppressed endogenous PSA expression (Figure 4d) (by approximately 25 and 45% for cyclin D3 and RD3, respectively) using strategies parallel to Figure 1b . Thus, a functional domain sufficient for AR association and modulation is conserved in multiple D-cyclins.
Cyclin D3 modulates androgen-dependent proliferation
The ability of accumulated cyclin D1 to suppress androgen-dependent proliferation is specific to ARpositive cells (Petre et al., 2002; Petre-Draviam et al., 2005) . This unexpected effect of D-cyclins on proliferation is also exhibited in liver cells, where cyclin D3 modulation of C/EBP inhibits cell cycle via CDK4-dependent means (Timchenko et al., 2006; Wang et al., 2006) . Therefore, the impact of cyclin D3 on cellular proliferation in AR-dependent cells was examined by transfecting LNCaP cells with expression plasmids encoding histone H2B-GFP (transfection marker) and cyclins D1 (positive control), D3, RD3 or control in Figure 1b and then transfected with the indicated plasmids. RNA was isolated 48 h after transfection, cDNA was generated and relative PSA expression quantitated by real-time PCR. Expression in vector-transfected cells were set to 1. Results shown are a representative experiment of three independent experiments, each performed with triplicate independent samples. Similar results were observed in each experiment. Data are presented as mean ± s.e.m. ANOVA, analysis of variance; AR, androgen receptor; DHT, 5a-dihydro-testosterone; PSA, prostate-specific antigen; RD, repressor domain; SDS-PAGE, SDS-polyacrylamide gel electrophoresis.
androgen-deprived media. Following transfection, cells were cultured in the presence of androgen for 32 h, and then subsequently labeled with bromodeoxyuridine (BrdU). As expected, cells transfected with cyclin D1 exhibited a 16% reduction in BrdU incorporation when compared with control ( Figure 5a ). As indicated, cyclin D3 and RD3 reduced androgen-dependent proliferation by approximately 20 and 30%, respectively, demonstrating that the RD3 is sufficient to suppress proliferation in AR-positive PCa cells.
To investigate the role of accumulated cyclin D3 on cell cycle position in LNCaP cells, flow cytometry was performed. As expected in AR-positive cells, ectopic cyclin D1 expression induced a marked increase in the G1 population as compared with control ( Figure 5b) ; similar results were observed with full-length cyclin D3 and RD3. Analyses were subsequently carried out in AR-negative PC3 cells, which do not require androgen stimulation for cell cycle progression (Kaighn et al., 1979) . The D-cyclins induced no statistically significant alterations in G1 (Figure 5c ). Thus, the impact of cyclin D3 on proliferation appears specific to androgendependent cells, and the RD3 is sufficient to slow cellular proliferation.
Cyclin D3 expression is altered in PCa progression
Given the ability of cyclin D3 to bind and modulate AR, cyclin D3 expression was analysed in primary PCa specimens. First, efficacy of cyclin D3 immunostaining was validated in LNCaP xenografts, which are positive for cyclin D3 and demonstrate exclusively nuclear expression (Figure 6a ). By contrast, concurrent staining of a tissue microarray of primary prostatic adenocarcinomas (n ¼ 67 of cores analysed) revealed a dramatically altered pattern. As exemplified in Figure 6b , little cyclin D3 was detected in the nucleus; rather cyclin D3 appeared almost exclusively cytoplasmic in low-grade primary tumors (Gleason o7; n ¼ 17). Overall levels of cyclin D3 diminished as a function of tumor grade, where high-grade tumors (n ¼ 50) showed markedly reduced cytoplasmic cyclin D3 and limited nuclear staining. These data indicate that cyclin D3 expression patterns may be significantly altered in local disease, potentially providing a mechanism whereby AR modulatory ability is lost. Nuclear cyclin D3 was most apparent upon examination of lymph node metastases, where two of the three examined metastatic tumors showed overt nuclear cyclin D3 staining (Figure 6b,  bottom panel) .
Finally, the relevance of cyclin D3 expression for cellular proliferation was examined by comparing cyclin D3 levels to the Ki-67 index. As shown, the highest proliferative indices were observed in tumors that were devoid of cyclin D3 (Figure 6c) . Tumors exhibiting the highest levels of cyclin D3 demonstrated no increased proliferative capacity as compared with negative or low expressing tumors. Thus, cyclin D3 is inversely correlated with the proliferative index in PCa cells, thus suggesting that loss of cyclin D3 may facilitate proliferation. Figure 5 Cyclin D1 and cyclin D3 transcriptional repression elicit similar effects on cellular progression. (a) LNCaPs were seeded onto poly-lysine-coated coverslips in six-well dishes prior to transfection with pcDNA3 (vector control), H2B-GFP (as a marker of transfection) and expression plasmids encoding cyclin D1, cyclin D3 or cyclin D3-RD in androgen-deprived media. Following transfections, cells were returned to androgen-proficient media (5% FBS) for approximately 32 h, and then incubated with BrdU for 16 h. Cells were fixed, stained, mounted and then counted by indirect immunofluorescence. The percentage of BrdU-positive transfected cells is plotted. One-way ANOVA was performed to determine statistical significance (*Po0.05). (b and c) LNCaPs (b) or PC3s (c) were transfected as described in (a). Cells were fixed in ethanol and then labeled with propidium iodide (PI) and subjected to flow cytometry to evaluate cell cycle position. Representative traces are shown for the LNCaPs and data are graphed as the mean percentage of at least three independent experiments of the G1 population±s.e.m. ANOVA, analysis of variance; BrdU, bromo-deoxyuridine; FBS, fetal bovine serum; LNCaP, lymph node prostate cancer; RD, repressor domain. Discussion D-cyclins harbor discrete roles in controlling transcription factor activity, and disruption of this process can perturb nuclear receptor activity (Coqueret, 2002; Ewen and Lamb, 2004; Fu et al., 2004; Knudsen, 2006 ). Here we demonstrate that cyclin D3 associates with and attenuates the ligand-dependent function of the AR in PCa cells. Underpinning mechanisms were attributed to disruption of AR N-C-terminal interaction and altered AR chromatin association, where accumulated cyclin D3 levels thereby attenuate AR-dependent cell proliferation. These functions proved CDK4-independent, and were manifested through a conserved repressor motif. Lastly, analyses of human tumors revealed that cyclin D3 expression is frequently restricted to the cytoplasm in low-grade prostatic adenocarcinomas and is reduced as a function of tumor grade, thus suggesting that cyclin D3 downregulation may provide a mechanism of heightened AR activity in PCa cells. Together, these data reveal a new facet of cell cycle-AR crosstalk in the prostate that may hold implications for PCa progression.
While this manuscript was in revision, Zong et al. (2007) demonstrated a potential CDK4-independent mechanism of cyclin D3-mediated repression of AR transcriptional activity and AR-dependent proliferation, whereby a trimeric complex (cyclin D3/CDK11p58/AR) can induce AR phosphorylation at Ser-308. This CDK11-dependent event led to the repression of AR transcription unit 1 activity and AR-dependent proliferation (Zong et al., 2007) . These data, in congruence with the data presented here, illustrate that cyclin D3 maintains the ability to repress AR transcriptional activity and AR-dependent proliferation.
Importantly, the ability of cyclin D3 to govern transcription factor activity has been linked to attenuation of cell cycle progression in other cell types. For example, the cyclin D3/CDK4 complex can directly phosphorylate C/ EBPa and promote its stabilization with Brm or CDK2, which inhibit cell cycle progression/proliferation in aged and young murine hepatocytes, respectively . Furthermore, analyses of murine livers revealed CUGBP1 as a substrate of cyclin D3/CDK4; following phosphorylation, CUGBP1 interacts with eIF2, which acts through C/EBP and (liver-enriched transcriptional inhibitory protein) to inhibit hepatocyte proliferation (Timchenko et al., 2006) . Lastly, cyclin D3 was shown to negatively regulate AML1 activity by competing with CBFb for AML1 binding, thereby diminishing AML1 target gene affinity and subsequently preventing cell cycle progression (Peterson et al., 2005) . The present data provide a third and distinct mechanism through which cyclin D3 can unexpectedly suppress cell proliferation.
Although these observations identify selected transcription factors as focal points of CDK4-dependent cyclin D3 activity, our data indicate that cyclin D3 regulates AR independently of CDK4. Several factors have been shown to be regulated by cyclin D3 through CDK4-independent mechanisms. Cyclin D3 was shown to bind the vitamin D receptor (VDR) and potentiate its activity in a dose-dependent manner. However, ectopic expression of CDK4/6 abrogated this activity, suggesting that CDK4 activation counterbalances the potentiating effects (Jian et al., 2005) . Thus, while cyclin D3 depends upon CDK4-kinase activity to control C/EBPa in liver cells, it appears to impinge on VDR and AR independently of CDK4 function (Timchenko et al., 2006; Wang et al., 2006 Wang et al., , 2007 . It will be intriguing to determine whether these CDK4-independent effects are reliant on the newly identified role of cyclin D3 in CDK11 activation (Zong et al., 2007) .
While these observations indicate that the mechanisms by which cyclin D3 regulates AR are distinct from those for regulating C/EBP or VDR, the present study reveals some parallels with cyclin D1 action, which utilizes at least two mechanisms to control AR activity. These mechanisms include abrogation of AR N-Cterminal interaction and require HDAC function. Both modes are required for repressor function, and are CDK4-independent (Knudsen et al., 1999; Reutens et al., 2001; Petre et al., 2002; Petre-Draviam et al., 2003; Burd et al., 2005) . As shown, cyclin D3 invokes similar mechanisms to repress ligand-dependent AR activity (Figure 1) , likely attributed to a conserved central repressor domain within cyclin D3. However, distinctions were noted, in that cyclin D1, but not cyclin D3, was detected at the PSA enhancer (LM Morey and KE Knudsen, in preparation) . By contrast, cyclin D3 reduced AR recruitment to this region under identical conditions (Figure 2b ). However, lack of cyclin D3 detection could be attributed to antibody constraints. These findings suggest that despite the conservation of the repressor domain, distinctions in cyclin D3 activity exist. In addition to disparity in AR control, it will be of interest to examine the effects elicited by cyclin D3 on VDR activity in the prostate, since VDR agonists inhibit cellular proliferation in PCa cells (Skowronski et al., 1993; Schwartz et al., 1994; Miller et al., 1995; Zhuang et al., 1997) , and cyclin D3 can potentiate VDR function (Jian et al., 2005) . Thus, although the ability of cyclin D3 to reduce cellular proliferation in PCa cells is most likely attributed to AR regulation, the impact of cyclin D3 on VDR function may bolster this effect.
Given the influence of cyclin D3 on nuclear receptor signaling, it was imperative to address the status of cyclin D3 in primary prostatic adenocarcinomas. Here, we showed that cyclin D3 localization is largely cytoplasmic in low-grade tumors and as tumor grade increases, total cyclin D3 expression is diminished. This profile is distinct from recent analyses of cyclin D1 expression, where although a large fraction of tumors score negative for cyclin D1, increased cytoplasmic expression was observed in a subset of tumors, and some nuclear expression is noted in higher grades (Comstock et al., 2007) . Total cyclin D3 expression is inversely correlated with Ki-67, whereas nuclear cyclin D1 corresponds with higher Ki-67. Analyses of cyclin D3 localization in other tumor types indicated that cyclin D3 expression is enhanced in renal and gastric tumors (Hedberg et al., 2002; Miehlke et al., 2002) . In renal cancer, high cyclin D3 expression correlated with high proliferative indices, and was detected in both the nucleus and cytoplasm (Hedberg et al., 2002; Miehlke et al., 2002) . These data are distinct from our observations where cyclin D3 expression was mainly localized to the cytoplasm and inversely correlated with tumor grade and Ki-67 index, indicating distinct roles for cyclin D3 activity in different tumor types.
In summary, we identified cyclin D3 as a co-repressor of ligand-dependent AR activity and proliferation, achieved through CDK4-kinase-independent mechanisms. Accumulated cyclin D3 attenuated the recruitment of AR to target gene loci and suppressed AR activity through defined mechanisms and a repressor motif similar to that of cyclin D1. These functions may be perturbed in PCa, as cyclin D3 is largely sequestered to the cytoplasm in this tumor type, is lost as a function of tumor grade and is inversely correlated to the proliferative index. Together, the data presented identify cyclin D3 accumulation as an influential mechanism to control the androgen response, and indicate that cyclin D3-mediated AR regulatory activity is likely perturbed in PCa.
Materials and methods
Cell culture, transfections and reporter assays Cell lines were obtained and cultured as previously described (Petre et al., 2002; Petre-Draviam et al., 2003 Braden et al., 2006; Burd et al., 2006) . Transient assays of AR function were previously described (Knudsen et al., 1999; Petre et al., 2002; Petre-Draviam et al., 2003; Burd et al., 2005 Burd et al., , 2006 . Plasmids All constructs were previously described (Arap et al., 1995 
Immunoprecipitations and immunoblots
Performed as previously described (Petre-Draviam et al., 2003 . Details provided in Supplementary Information.
Flow cytometry
LNCaP and PC3 cells were transfected as previously mentioned (Chen and Okayama, 1987; Petre et al., 2002; PetreDraviam et al., 2003) . Flow cytometry was performed as previously described (Petre-Draviam et al., 2003) .
BrdU incorporation
Bromodeoxyuridine incorporation was performed as previously described (Petre et al., 2002; Petre-Draviam et al., 2003) .
Reverse transcription PCR Amplification of PSA and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and real-time PCR were performed as previously described (Petre-Draviam et al., 2003; Wetherill et al., 2006) .
Histology
Hematoxylin and eosin staining, immunohistochemical staining for cyclin D3 and Ki-67, scoring, analyses and images were performed as previously described (Wetherill et al., 2006; Comstock et al., 2007) .
Chromatin immunoprecipitation
Lymph node prostate cancer cells were transfected, treated with 10 nM DHT for 3 h and harvested for ChIP analysis as previously described (Link et al., 2005) , with modifications described in Supplementary Information.
